Format

Send to

Choose Destination
Br J Ophthalmol. 2018 Oct 26. pii: bjophthalmol-2018-312724. doi: 10.1136/bjophthalmol-2018-312724. [Epub ahead of print]

Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning.

Author information

1
Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
2
Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan harada-tk@igakuken.or.jp.

Abstract

Glaucoma is one of the leading causes of vision loss in the world. Currently, pharmacological intervention for glaucoma therapy is limited to eye drops that reduce intraocular pressure (IOP). Recent studies have shown that various factors as well as IOP are involved in the pathogenesis of glaucoma, especially in the subtype of normal tension glaucoma. To date, various animal models of glaucoma have been established, including glutamate/aspartate transporter knockout (KO) mice, excitatory amino acid carrier 1 KO mice, optineurin E50K knock-in mice, DBA/2J mice and experimentally induced models. These animal models are very useful for elucidating the pathogenesis of glaucoma and for identifying potential therapeutic targets. However, each model represents only some aspects of glaucoma, never the whole disease. This review will summarise the benefits and limitations of using disease models of glaucoma and recent basic research in retinal protection using existing drugs.

KEYWORDS:

degeneration; drugs; experimental – animal models; experimental – laboratory; glaucoma

Free full text

Conflict of interest statement

Competing interests: None declared.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center